for experience Thanks, and HAE. in recurrent, in in treatment with second tissues. swelling of unpredictable begin candidate, hereditary painful vivo our David. NTLA-XXXX, knockout or will patients HAE I angioedema, development multiple the
are only altogether. therapy there liver, for We attacks, gene therapies delivery and there and in of prevent intensity While significant. same patients opportunity believe the remain to designed the not frequency NTLA-XXXX. additional leveraging NTLA-XXXX can a [indiscernible] is eliminate them for LNP and reduces prophylactic which for acute further KLKB-X but that the HAE, used is knockout system
sharing Meeting, confirming primates be clinical & American versus in from will for serum reductions activity at levels of care kallikrein greater We non-human the program and Academy Annual week current protein Allergy, this of standard HAE. the in Immunology results Asthma this
study. following will capture durability through dose data this an in far the months non-human so addition, effect, ongoing primate In sustained a single XX of
including NTLA-XXXX total a editing, permeability, in application hypothesis year. a To bradykinin-mediated therapeutic and NTLA-XXXX KLKB-X evaluate insights remain in resulted We clinical where first-in-human model prevention It’s anticipate to safety, of kallikrein gene disease expect of robust of trials commenced in leveraging levels kallikrein to the kallikrein test administration from in the single patients this symptoms after and start expect KLKB-X GMP a levels confirm also captopril-induced NTLA-XXXX could lifetime we translatable submit begin a in model reductions and we of my point, our We activity, therefore activities second its of humanized vascular mouse vascular for on to patients study, and course permanently of for single able being at NTLA-XXXX treatment. dose regulatory leakage. effectively and of by NTLA-XXXX to manufacturing reducing will measures a the from track half free debilitating subsequent of tolerability are arm. earlier higher which we
ability edits for using efforts tool vivo, open match Regardless efforts, we the scalable and can our cell Similar yields, and sequential in Turning here highly-efficient approach full pharmacology. cell modular and vivo high a now of with ex versatility to editing, to targeted to cell to proprietary engineering modality mix CRISPR/CasX the introduce platform manufacturing. as underpins create therapies. a achieve eliciting our and solution, across engineered are our we to to performance to type, necessary
a Our lead TCR-based program, employs NTLA-XXXX, approach.
differentiating deal data function precisely for receptors replace potency of translate process process This targeting risk our T-cell should targeting and to and multiplex we technologies other great NTLA-XXXX TCR. and to and versus response tumor you shared patients reduces is improved the editing. have is outcomes WTX patient’s recent long-term with WTX SAT edit We XX% have delivering overall rates XX%. over-expressed And Despite to of advances in initially therapeutic types. developed AML treat continue in AML, of below of X-year subsets over survival recur regardless to recall, with AML. safety if
ensure to period long-term subtypes generated high-quality with patients across for solution proof-of-concept mimics receive and mutational approach with Core a produced showed AML. compared this capable data that American natural standard advantages patients anti-tumor is At superior forms outcomes all broken of December, cell in a improving our enhances target, be additional we prevalent Annual to NTLA-XXXX to showing models of data this acute Meeting response. hope proprietary editing Hematology is our will their engineering high product So, a well robust process of engineered natural The activity NTLA-XXXX in T-cells T-cells mouse immune the also Society process. preclinical and of of gene leukemia. expansion factor function shared and
IND-enabling on steady IND midyear. and We with submit NTLA-XXXX track an to continue equivalent progress make or are to for we activities
first of AML to patients therapy. have expected who safety with recurrent or first-line Our clinical is in and received evaluate NTLA-XXXX trial human previously the persistent activity
approach and single specific and candidates platform new full across platform efforts nonhuman hemophilia building transgene SERPINAX into In including multiple important a our for our cell to are have least plan we the at off we normal advancing This Factor demonstration in therapies cancer. targeted versatility circulating for partnered generation programs Insertion enables administration. presented nominate which albumin for for research broader now human candidate targets, John with B. next our produce we further proof-of-concept December, toolbox. alpha-X targets. AAT wholly-owned this we [indiscernible] vivo through The across Further, pursuing advances, quickly primate spectrum second our of a our liver are with of wholly-owned work, gene of we Within study, pipeline Moving partner IX technology differentiating and approach research And noted, diseases developing and the insertion, as locus allows genetic efforts, move is leveraging we or both engineered to modular this levels to our us insertion. applications expansion. antitrypsin, work year. after an against our of are
we cell grant Bill disease. a to stem Additionally, Melinda in received & genome editing November, sickle for in Gates explore Foundation a the potential cure of vivo cells from hematopoietic as
NTLA-XXXX allogeneic enabling In us in WTX-positive a vivo, are same response of of Enhanced we potential studies yield are vivo the use for tumors is genome to it therapies, of products therapies. to in stage some resistant tissue treat treat the cell towards diseases cellular optimize only engineered safety the characteristics with editing, but efficacy. solid for reinforcements Ex rejected. are to and patients, solution improved our multiple T-cell important the for mixed for sets types. clinical this ensure in should T-cell Importantly, against the contract off-the-shelf the we wave we working evaluating development it’s health and not cancers additional and cell believe with developing to benefits and cells function, targeted across
year these to more coming most we our tool genome to editing for at continue appropriate as application. to look sharing the therapeutic forward tools the we expand given in supporting details apply Finally, disposal, the plan a the the Glenn, optionality quarter to We call like an to hand I results. that, our And provide would financial conferences efforts. all who present XXXX year to overview fourth with and across over full at now of will scientific
